SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
0.223
-0.010 (-4.20%)
At close: Nov 4, 2024, 4:00 PM
0.229
+0.005 (2.33%)
After-hours: Nov 4, 2024, 5:53 PM EST

Company Description

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.

Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.

The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form.

It also has an agreement with The Israeli Medical Center for Alzheimer’s to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021.

SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

SciSparc Ltd.
SciSparc logo
Country Israel
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Oz Adler

Contact Details

Address:
Tower A, 2nd Floor
Tel Aviv, 6971916
Israel
Phone 972 7 334 47180
Website scisparc.com

Stock Details

Ticker Symbol SPRC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001611746
CUSIP Number M82618105
ISIN Number IL0010951403
SIC Code 5500

Key Executives

Name Position
Oz Adler CPA Chief Executive Officer and Chief Financial Officer
Itschak Shrem President and Director
Dr. Adi Zuloff-Shani Ph.D. Chief Technologies Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 6-K Report of foreign issuer
Oct 23, 2024 6-K Report of foreign issuer
Oct 22, 2024 6-K Report of foreign issuer
Sep 27, 2024 6-K Report of foreign issuer
Sep 26, 2024 F-4 Filing
Sep 26, 2024 6-K Report of foreign issuer
Sep 23, 2024 6-K Report of foreign issuer
Sep 16, 2024 6-K Report of foreign issuer
Sep 11, 2024 425 Filing
Sep 11, 2024 6-K Report of foreign issuer